In our latest thought leader interview we explore the intersection between epigenetic therapy and immunotherapy.

Gems from the ASCO17 poster hall

Much of the IO focus to date has been on monotherapies rather than combos, although that situation is slowly changing.

What we can also expect to see are the emergence of regimens, long the bedrock of traditional cancer therapy approaches.

As we learn how to bucket more discrete populations based on the underlying biology of the tumour microenvironment, so we will see a more IFTTT (If this then that) approach evolve in order to fix or improve a situation before or after attempting the core therapy. It might require a focus on changing the immunosuppressive or inhibitory factors, for example, or addressing factors that induce primary resistance upfront. The possibilities are endless.

Obviously, there are a number of ways to do this from chemotherapy and radiotherapy to epigenetic agents to targeted therapies – these traditional treatments are not going to go away, but I can see a future where we see more integration based on a patient’s underlying immune status. It won’t be the zero sum game many analysts seem to think it might be.

In the past, we have covered chemotherapy, radiotherapy and targeted therapies and looked at how they might be employed with immunotherapies in various guises. In this latest thought leader interview, we look at a different approach, epigenetic therapy and other novel immunotherapies.

Here, we combine two popular types of posts – Gems from the Poster Halls with an Expert Interview  – for detailed look at one particular area of research that is beginning to look quite intriguing.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

Posted by